lisocabtagene maraleucel,ibrutinib,venetoclax
BMS,Roche,Abbvie
['lymphoma', 'liso-cel', 'lymsm', 'cll', 'transcend cll 004', 'cll 004', 'transcend,(-nhl-001),(-nhl 001),(-nhl001),(-nhl-006),(-nhl 006),(-nhl006),(-pilot-017006),(-pilot017006),(-pilot 017006)']
congress|#asco23 tanya siddiqi repots on the primary analysis of transcend cll 004 investiating liso-cel in patients with r/r cll/sll. results support the use of liso-cel in patients with r/r cll/sll with durable cr/cri rate and high umrd rates #lymsm #lymphoma 
A global education platform providing clinical updates on a range of lymphoma subtypes and chronic lymphocytic leukemia (#CLL) #lymsm